We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Low Cost Biosensor to Be Based on Printing Technologies

By LabMedica International staff writers
Posted on 14 Sep 2011
Scientists intend to use the latest printing technologies to develop a low cost biosensor capable of diagnosing a range of health conditions.

Living antibodies will be placed into a suitable ink and then printed onto a compatible substrate or material to form a disposable sensor, capable of being mass-produced at low cost. More...
The printed array of antibodies speeds up the testing process while reducing the expertise and complexity of equipment needed--introducing the possibility of hand held electronic scanners and far quicker diagnosis.

Antibody based assays are routinely used to detect specific medical conditions but use of these tests is limited because they need to be carried out in laboratories by highly skilled technicians, which is costly and time consuming.

The team developing the new technique is led by Prof. Tim Claypole, head of Swansea University's Welsh Center of Printing and Coating (Wales, United Kingdom). Prof. Claypole said the project is at the forefront of international research and represents a major advance in the printing of biomedical sensors.

“The availability of low cost, disposable sensor technology is a core requirement for the early diagnosis of disease. The use of antibodies as sensors targeted to detect specific human conditions is regarded as one of the next major advances in health care.

“Volume printing is also the most practical method to achieve low cost disposable sensor technology. This will take innovation from the bench to the bedside and develop the tools and technologies to move the process of diagnosis forward and bring it into the surgery and home.”

In addition to allowing some aspects of patient care to be moved from the hospital or laboratory to the GP surgery, the new biosensor technology could also be useful in emergency situations and in remote areas.

The project is supported by the Welsh Government's Academic Expertise for Business (A4B), an EU funded initiative to stimulate and encourage collaboration between educational institutions and industry.

The initial focus will be developing a proof of concept device that will open opportunities to develop antibody sensors to diagnose a broad range of health conditions.

Related Links:

Swansea University's Welsh Center of Printing and Coating
Welsh Government's Academic Expertise for Business




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.